Acoltremon: First Approval.
Arnold Lee
https://pubmed.ncbi.nlm.nih.gov/40736647/Actively Recruiting
Led by University of South Florida · Updated on 2026-08-12
50
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are evaluating how acoltremon ophthalmic solution 0.003% affects tear production in patients with stage 1 neurotrophic keratopathy, a condition where corneal tissue breakdown reduces tear production. The study aims to assess if this treatment can improve wound healing, repair, and nerve function of the cornea, potentially benefiting those with this ocular surface disease. It is a Phase 4, open-label study conducted by the University of South Florida. Participants will receive topical acoltremon 0.003% eye drops twice daily in both eyes for 8 weeks. If both eyes qualify, the eye with worse vision is chosen for study assessments. Those who do not respond well to the treatment may be removed from the trial and receive standard care instead. The study focuses on treatment effects over the 8-week period. During the study, participants will be monitored through tests such as the unanesthetized Schirmer test to measure tear production, corneal staining, and best corrected distance visual acuity. These evaluations occur from baseline day 1 through week 8 to track changes. The primary outcome is the Schirmer test score at 8 weeks. Participants will be followed closely for safety and treatment response throughout the 8 weeks of participation.
CONDITIONS
Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
P
Pedram Hamrah, MD
S
Susan Sherouse
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of South Florida
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Acoltremon 0.003% solution | Supportive care (lubricants, serum tears, amniotic therapies) |
|---|---|---|
| What it is | An investigational eye drop, Acoltremon 0.003% solution applied twice daily in the selected study eye over 8 weeks | Supportive ocular surface treatments such as preservative‑free lubricants, serum tears or amniotic membrane therapy |
| Role in the trial | Single‑arm therapeutic intervention under study | Not part of this study but represents background care offered outside trial |
| Primary purpose | To treat stage I neurotrophic keratopathy and improve ocular surface disease signs and symptoms in tear‑deficient patients | To protect and hydrate the ocular surface and promote epithelial health |
| How it is given or performed | Instilled as eye drops twice daily into one qualifying study eye for 8 weeks | Applied as lubricating drops, serum‑derived tears or amniotic membrane per clinician preference |
| Evidence status | Efficacy in stage I NK not yet established by this trial | Supportive therapies are accepted to maintain epithelial health though not curative |
| Important limitations | Single‑arm design without control group limits comparative assessment | Supportive therapies do not address nerve regeneration and may require frequent application |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive Acoltremon 0.003% ophthalmic solution twice daily in both eyes for 8 weeks. The eye with worse vision is studied if both qualify. Participants may be removed if the treatment is not effective.
Multiple visits during treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Arnold Lee
https://pubmed.ncbi.nlm.nih.gov/40736647/Guruprasad R Pattar, David Wirta, Gary Jerkins...
https://pubmed.ncbi.nlm.nih.gov/41038456/Yang Zhou, Wenzhu Zhang, Fusheng Sun
https://pubmed.ncbi.nlm.nih.gov/40571589/Muddassir Khalid, Esha Zahid, Muhammad Shaheer
https://pubmed.ncbi.nlm.nih.gov/41377326/University of South Florida
Lead Sponsor